Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Zhi Tian Lai Spends CN¥6.0m On Zhongzhi Pharmaceutical Holdings Stock
Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders (or potential shareholders) will be happy to see that the Chairman, Zhi Tian Lai, recently bought a whopping HK$6.0m worth of stock, at
Zhongzhi Pharmaceutical (03737.HK) received 5 million additional shares of common stock worth HK$6 million from Crystal Talent Investment Group Limited
On April 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 22, Crystal Talent Investment Group Limited increased its share holdings of $Zhongzhi Pharmaceutical (03737.HK) by $5 million at an average price of HK$1.2 per share on April 19, worth about HK$6 million. After the increase in holdings, Crystal Talent Investment Group Limited's latest shareholding was 494 million shares, and the good position ratio increased from 56.60% to 57.18%. book
中智藥業:二零二三年年報
Zhongzhi Pharmaceutical (03737.HK) received 3.162 million additional shares of common stock from Crystal Talent Investment Group Limited, worth approximately HK$3.8893 million
On April 17, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 17, Crystal Talent Investment Group Limited increased its share holdings of $3.162 million in common shares at an average price of HK$1.23 per share on April 16, with an average price of HK$1.23 million per share, worth approximately HK$3.8893 million. After the increase in holdings, Crystal Talent Investment Group Limited's latest shareholding number was 489 million shares, and the good position ratio increased from 56.24% to 56
Zhongzhi Pharmaceutical (03737.HK) received 2.259 million additional shares of common stock from Crystal Talent Investment Group Limited, worth approximately HK$2,643,300
On April 16, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 16, Crystal Talent Investment Group Limited increased its share holdings of $2.259,000 of $Zhongzhi Pharmaceutical (03737.HK) with an average price of HK$1.1701 per share on April 15, worth about HK$2,643,300. After the increase in holdings, Crystal Talent Investment Group Limited's latest shareholding number was 486 million shares, and the good position ratio rose from 55.97%
Zhongzhi Pharmaceutical (03737.HK) was granted by Crystal Talent Investment Group Limited to increase its common share holdings by 3.198,000, worth approximately HK$3.837,600
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Crystal Talent Investment Group Limited increased its share holdings of $3.198,000 in common shares of $Zhongzhi Pharmaceutical (03737.HK) with an average price of HK$1.2 per share, worth about HK$3.837,600 on April 12. After the increase in holdings, Crystal Talent Investment Group Limited's latest shareholding was 483 million shares, and the good position ratio rose from 55.60% to 55.
Zhongzhi Pharmaceutical (03737.HK) received 2.68 million additional shares of common stock from Crystal Talent Investment Group Limited, worth approximately HK$3.242,800
On April 12, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 12, Crystal Talent Investment Group Limited increased its shares of $2.68 million in common shares of $Zhongzhi Pharmaceutical (03737.HK) at an average price of HK$1.21 per share, worth approximately HK$3.242,800. After the increase in holdings, Crystal Talent Investment Group Limited's latest shareholding number was 480 million shares, and the good position ratio rose from 55.29% to 55.60
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Zhongzhi Pharmaceutical (03737.HK) received 3.05 million additional shares of common stock worth approximately HK$3,513 million from Crystal Talent Investment Group Limited
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Crystal Talent Investment Group Limited increased its share holdings of $Zhongzhi Pharmaceutical (03737.HK) by $3.05 million at an average price of HK$1.1518 per share on April 3, worth about HK$3,513 million. After the increase in holdings, Crystal Talent Investment Group Limited's latest shareholding number was 478 million shares, and the good position ratio increased from 54.94% to 55.29%
[Revised by the Stock Exchange] Zhongzhi Pharmaceutical (03737.HK) was granted by Lai Zhi-fen to increase its common share holdings by 3.36 million shares, worth approximately HK$3,964,800
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Lai Chi-fen increased his shareholding of $3.36 million in common shares of $Zhongzhi Pharmaceutical (03737.HK) at an average price of HK$1.18 per share on April 2, with a value of about HK$3.964,800. After the increase in holdings, Lai Zhifian's latest shareholding was 544 million shares, and the good position ratio rose from 62.59% to 62.98%. This transaction involves another related party: Jiang Lixia. Additional information:. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, the majority shareholder (holding 5% of the shares or
Chairman of Zhongzhi Pharmaceutical Holdings Zhi Tian Lai Buys More Stock
Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders (or potential shareholders) will be happy to see that the Chairman, Zhi Tian Lai, recently bought a whopping HK$4.0m worth of stock, at
Zhongzhi Pharmaceutical (03737.HK) received 3.36 million shares from Chairman and Executive Director Lai Zhijian
Gelonghui, April 5 | According to the latest equity disclosure data of the Stock Exchange, on April 3, 2024, Zhongzhi Pharmaceutical (03737.HK) was granted an increase of 3.36 million shares by Chairman and Executive Director Lai Zhifen on the market at an average price of HK$1.18 per share, involving approximately HK$3.965 million. After the increase in holdings, Lai Zhifian's latest shareholding was 543,899,800 shares, and the shareholding ratio increased from 62.59% to 62.98%.
Zhongzhi Pharmaceutical (03737.HK) received 3.36 million additional shares of common stock from Crystal Talent Investment Group Limited, worth approximately HK$3.964,800
On April 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 3, Crystal Talent Investment Group Limited increased its share holdings of $3.36 million in common shares of $Zhongzhi Pharmaceutical (03737.HK) at an average price of HK$1.18 per share on April 2, worth about HK$3.364,800. After the increase in holdings, Crystal Talent Investment Group Limited's latest shareholding was 474 million shares, and the good position ratio increased from 54.55% to 54.94%.
No Data